Most current findings derive primarily from animal models and small pilot studies, with definitive efficacy and safety in broad patient populations yet to be established
Note that supplemental magnesium has an upper safe limit (typically 400mg/day for adults) and higher doses can cause diarrhoea
People who took the pill in clinical trials also experienced similar side effects as those on injectables, including gastrointestinal issues such as nausea, diarrhea and vomiting, according to Novo Nordisk
Coverage Baseline Previously unavailable under Medicare Part D Only 13 states cover them in Medicaid (KFF HMA survey) 19% of large employers cover GLP-1s for obesity, though 43% of employers with 5,000+ employees offer coverage (KFF 2025 survey) Current Expansion ~50% of CVS Caremark clients now provide coverage for weight loss Medicare GLP-1 Bridge program launches coverage for eligible Medicare Part D patients 7/1/26 This aligns with a recent survey from Business Group on Health that found 67% of the surveyed employers now cover GLP-1s for weight loss (though a reduction is expected for 2027)
NAION Symptoms May Include: Sudden blurred or dim vision (often in one eye) Loss of peripheral (side) vision Dark patches in your field of view Reduced contrast sensitivity or color perception Sudden vision loss upon waking Difficulty seeing in low light or bright glare Ozempic and the Risk of NAION In August 2024, a groundbreaking study published in JAMA Ophthalmology identified a significantly higher rate of NAION among people taking semaglutide (the active ingredient in Ozempic and Wegovy) medications compared to those on non-semiglutide diabetes medications
